Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
IC – 171.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 4, April, p. 547–551

doi: 10.17219/acem/68363

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Liver dysfunction in sepsis

Ewa A. Woźnica1,A,B,C,D, Małgorzata Inglot2,C,E, Ryszard K. Woźnica3,C,E, Lidia Łysenko1,C,E,F

1 Department of Anaesthesiology and Intensive Therapy, Wroclaw Medical University, Poland

2 Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiences, Wroclaw Medical University, Poland

3 Altnagelvin Area Hospital, Londonderry, UK

Abstract

Despite continuous progress in medicine, sepsis remains the main cause of deaths in the intensive care unit. Liver failure complicating sepsis/septic shock has a significant impact on mortality in this group of patients. The pathophysiology of sepsis-associated liver dysfunction is very complicated and still not well understood. According to the Surviving Sepsis Campaign (SSC) Guidelines, the diagnosis of liver dysfunction during sepsis is based on the increase in bilirubin concentration >2 mg/dL and the occurrence of coagulation disorders with INR > 1.5. The lack of specificity and ability to distinguish acute liver failure from previous liver dysfunction disqualifies bilirubin as a single parameter reflecting the complex liver function. Clinical manifestations of sepsis-associated liver dysfunction include hypoxic hepatitis, sepsis-induced cholestasis and dysfunction of protein synthesis manifesting with, e.g., coagulopathies. Detoxifying liver dysfunction, which is associated with an increase in serum ammonia concentration, manifesting with e.g., confusion, loss of consciousness and hepatic encephalopathy, may be disguised by analgosedation used in the intensive care unit. To determine a liver dysfunction in a critically ill patient, the concept of shock liver may be used. It is a complex syndrome of hemodynamic, cellular, molecular and immunologic changes leading to severe liver hypoxia. In clinical practice, there is no standardized diagnostic panel that would allow for an early, clear diagnosis of acute liver dysfunction, and there is no therapeutic panel enabling the full restoration of damaged liver function. The aim of the article is to present the pathophysiology and clinical manifestations of sepsis-associated liver dysfunction.

Key words

sepsis, MODS, liver dysfunction, shock liver

References (50)

  1. Blanco J, Muriel-Bombín A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: A Spanish multicentre study. Crit Care. 2008;12:R158.
  2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–1554.
  3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med.2001;29:1303–1310.
  4. National Institute of General Medical Sciences – Sepsis Fact Sheet. http://www.nigms.nih.gov/Education/Pages/factsheet_sepsis.aspx Accessed on December 28, 2016.
  5. Kübler A, Adamik B, Ciszewicz-Adamiczka B, Ostrowska E. Severe sepsis in intensive care units in Poland – Point prevalence study in 2012 and 2013. Anaesthesiol Intensive Ther. 2015;47:315–319.
  6. Kübler A, Adamik B, Durek G, et al. Results of the severe sepsis registry in intensive care units in Poland from 2003–2009. Anaesthesiol Intensive Ther. 2015;47:7–13.
  7. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: Pathophysiology and prognosis. Intern Med. 2007,46(14):1063–1070.
  8. Kobashi H, Toshimori J, Yamamoto K. Sepsis-associated liver injury: Incidence, classification and the clinical significance. Hepatol Res. 2013;43(3):255–266.
  9. Aninat C, Seguin P, Descheemaeker P, Morel F, Malledant Y, Gullouzo A. Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med. 2008,36:848–854.
  10. Kolios G, Valatas V, Manousou P, Xidakis C, Notas G, Kouroumalis E. Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells. Mol Cell Biochem. 2008;319:91–98.
  11. Doi F, Goya T, Torisu M. Potential role of hepatic macrophages in neutrophil-mediated liver injury in rats with sepsis. Hepatology. 1993;17:1086–1094.
  12. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101(10):3765–3777.
  13. Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. Burns Trauma. 2014;2:97–105.
  14. Kwok W, Lee SH, Culberson C, Korneszczuk K, Clemens M. Caveolin-1 mediates endotoxin inhibition of endothelin-1-induced endothelial nitric oxide synthase activity in liver sinusoidal endothelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;297(5): G930–G939.
  15. Hyun-Ae Eum, Sang-Won Park, Sun-Mee Lee. Role of nitric oxide in the expression of hepatic vascular stress genes in response to sepsis. Nitric Oxide. 2007;17:126–133.
  16. Yeager ME, Belchenko DD, Nguyen CM, Colvin KL, Ivy DD, Stenmark KR. Endothelin-1, the unfolded protein response, and persistent inflammation: Role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2012;46:14–22.
  17. Bellisai F, Morozzi G, Scaccia F, et al. Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis. Int J Immunopathol Pharmacol. 2011;24:261–264.
  18. Brauner JS, Rohde LE, Clausell N. Circulating endothelin-1 and tumor necrosis factor-a: Early predictors of mortality in patients with septic shock. Intensive Care Med. 2000;26:305–313.
  19. Nesseler N, Launey Y, Aninat C, Morel F, Mallédant Y, Seguin P. Clinical review: The liver in sepsis. Critical Care. 2012;16:235.
  20. Bukovska G, Kery V, Kraus JP. Expression of human cystathionine beta-synthase in Escherichia coli: Purification and characterization. Protein Expr Purif. 1994;5:442–448.
  21. Blachier F, Davila AM, Mimoun S, et al. Luminal sulfide and large intestine mucosa: Friend or foe? Amino Acids. 2010;39:335–347.
  22. Zhang H, Zhi L, Moore PK, Bhatia M. Role of hydrogen sulfide in cecal ligation and puncture induced sepsis in the mouse. Am J Physiol Lung Cell Mol Physiol. 2006;290:L1193–1201.
  23. Altaany Z, Moccia F, Munaron L, Mancardi D, Wang R. Hydrogen sulfide and endothelial dysfunction: Relationship with nitric oxide. Curr Med Chem. 2014;21(32):3646–3661.
  24. EJ Norris, CR Culberson, S Narasimhan, MG Clemens. The liver as a central regulator of hydrogen sulfide. Shock. 2011;36(3):242–250.
  25. Pannen BHJ, Köhler N, Hole B, Bauer M, Clemens MG, Geiger KK. Protective role of endogenous carbon monoxide in hepatic microcirculatory dysfunction after hemorrhagic shock in rats. J Clin Invest. 1998,102:1220–1228.
  26. Hoetzel A, Dolinay T, Schmidt R, Choi AMK, Ryter SW. Carbon monoxide in sepsis. Antioxid Redox Signal. 2007;11(9):2013–2026.
  27. Brouarda S, Otterbeinb LE, Anratherc J, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. JEM. 2000;192(7):1015–1026.
  28. Wunder C, Brock RW, Frantz S, et al. Carbon monoxide, but not endothelin-1, plays a major role for the hepatic microcirculation in a murine model of early systemic inflammation. Crit Care Med. 2005;33:2323–2331.
  29. Strassburg CP. Gastrointestinal disorders of the critically ill. Shock Liver. Best Pract Res Clin Gastroenterol. 2003;17:369–381.
  30. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339:1217–1227.
  31. Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis. 2008;12:151–172. ix.
  32. Moseley RH. Sepsis and cholestasis. Clin Liver Dis. 2004;8:83–94.
  33. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology. 2007;45(1):230–241.
  34. Dahn MS, Lange P, Lobdell K, Hans B, Jacobs LA, Mitchell RA. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery. 1987;101:69–80.
  35. Henrion J. Hypoxic hepatitis. Liver Int. 2012;32(7):1039–1052.
  36. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH): Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330.
  37. Lipinska-Gediga M. Sepsis and septic shock-is a microcirculation a main player? Anaesthesiol Intensive Ther. September 23, 2016. doi: 10.5603/AIT.a2016.0037. [Epub ahead of print]
  38. Lisman T, Leebeek FWG. Hemostatic alterations in liver disease: A review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007;24:250–258.
  39. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013;41(2):580–637.
  40. Sakka S. Assessing liver function. Curr Opin Crit Care. 2007;13:207–214.
  41. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638–1652.
  42. Kaffarnik, Lock JF, Vetter H, et al. Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: A prospective study with the LiMAx test. Crit Care. 2013;17(5):R259.
  43. Vos JJ, Wietasch JKG, Absalom AR, Hendriks HGD, Scheeren TWL. Green light for liver function monitoring using indocyanine green? An overview of current clinical applications. Anaesthesia. 2014;69:1364–1376.
  44. Janssen MW, Druckrey-Fiskaaen KT, Omidi L, et al. Indocyanine green R15 ratio depends directly on liver perfusion flow rate. J Hepatobiliary Pancreat Sci. 2010;17:180–185.
  45. Kim GY, Bae KS, Noh GJ, Min WK. Estimation of indocyanine green elimination rate constant k and retention rate at 15 min using patient age, weight, bilirubin and albumin. J Hepatobiliary Pancreat Sci. 2009;16:521–528.
  46. Sauer IM, Goetz M, Steffen I, et al. In vitro comparison of the Molecular Adsorbent Recirculation System (MARS) and single-pass albumin dialysis (SPAD). Hepatology. 2004;39(5):1408–1414.
  47. Woznica R. Single Pass Albumin Dialysis for treatment of the acute liver failure – A case report. Med Intens Ratunk. 2007;10(4):233–237.
  48. Herrine SK. Liver injury caused by drugs. http://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/drugs-and-the-liver/liver-injury-caused-by-drugs Accessed on December 28,2016.
  49. La Mura V, Pasarín M, Meireles CZ, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology. 2013;57:1172–1181.
  50. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial. Gastroenterology. 2009;136:1651–1658.
© Wroclaw Medical University